Modulation of the GABAergic pathway for the treatment of fragile X syndrome
Reymundo Lozano,1,2 Emma B Hare,1,2 Randi J Hagerman1,2 1MIND Institute, 2Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA Abstract: Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is cau...
Guardado en:
Autores principales: | Lozano R, Hare EB, Hagerman RJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/93aa0c19c4ba410d9e40f0e9d2a11c33 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the role of antipsychotics in the treatment of Tourette syndrome
por: Huys D, et al.
Publicado: (2012) -
Treatment of Lennox-Gastaut syndrome: overview and recent findings
por: Kenou van Rijckevorsel
Publicado: (2008) -
Exploring diazoxide and continuous glucose monitoring as treatment for Glut1 deficiency syndrome
por: Santhi N. Logel, et al.
Publicado: (2021) -
Influence of drug treatment with antidepressants and antipsychotics on plasma urea levels
por: Lozano Ortiz R
Publicado: (2012) -
Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine
por: Lindquist S, et al.
Publicado: (2011)